title: Didanosine (ddI) and zidovudine (ZDV) susceptibilities of human immunodeficiency virus (HIV) isolates from long-term recipients of ddI.
abstract: Thirty HIV isolates, obtained from 15 patients before and after receiving single drug therapy with didanosine (ddI), were examined for sensitivity to ddI and zidovudine (ZDV) using a peripheral blood mononuclear leukocyte (PBML)-based assay. Fourteen of the patients had ARC, one had AIDS and 12 had received previous therapy with ZDV. After a median of 1 year of ddI therapy, isolates were significantly less sensitive to ddI than were isolates obtained prior to therapy (P = 0.03). A decrease in ddI sensitivity was observed in ten of the 15 isolate pairs. In contrast to ddI susceptibilities, sensitivity to ZDV increased over the same period of time (P = 0.03). Additional isolates were obtained from four patients who received ddI monotherapy for 2 years. Three of these isolates demonstrated no change in ddI sensitivity compared to baseline. No correlation could be made in this study between development of decreased ddI sensitivity and serum p24 levels, CD4 counts, or clinical outcome. Decreased ddI sensitivity occurs frequently among HIV isolates obtained from long-term recipients of ddI. This decreased sensitivity is modest in degree and is of unknown clinical significance.
authors.affiliation: University of Rochester Medical Center, New York.
authors.forename: R C
authors.initials: RC
authors.lastname: Reichman
authors.forename: N
authors.initials: N
authors.lastname: Tejani
authors.forename: J L
authors.initials: JL
authors.lastname: Lambert
authors.forename: J
authors.initials: J
authors.lastname: Strussenberg
authors.forename: W
authors.initials: W
authors.lastname: Bonnez
authors.forename: B
authors.initials: B
authors.lastname: Blumberg
authors.forename: L
authors.initials: L
authors.lastname: Epstein
authors.forename: R
authors.initials: R
authors.lastname: Dolin
mesh_terms: D000386:AIDS-Related Complex / Q000097:blood / Q000188:drug therapy / Q000382:microbiology; D000163:Acquired Immunodeficiency Syndrome / Q000097:blood / Q000188:drug therapy / Q000382:microbiology; D000328:Adult; D001483:Base Sequence; D015496:CD4-Positive T-Lymphocytes; D004279:DNA, Viral / Q000235:genetics; D016049:Didanosine / Q000494:pharmacology* / Q000627:therapeutic use; D004352:Drug Resistance, Microbial; D005260:Female; D015751:Genes, pol; D016655:HIV Core Protein p24 / Q000097:blood; D015497:HIV-1 / Q000187:drug effects* / Q000235:genetics / Q000302:isolation & purification; D006801:Humans; D007958:Leukocyte Count; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D008969:Molecular Sequence Data; D013997:Time Factors; D015215:Zidovudine / Q000494:pharmacology*
chemical_list: D004279:DNA, Viral; D016655:HIV Core Protein p24; D015215:Zidovudine; D016049:Didanosine